The impact of GGH -401C>T polymorphism on cisplatin-based chemoradiotherapy res...

• Autor(es): Silva, Inês Hilário ; Silva, Cristina Nogueira ; Figueiredo, Tiago ; Lombo, Liliana ; Faustino, Ilda ; Catarino, Raquel ; Nogueira, Augusto ; Pereira, Deolinda ; Medeiros, Rui
• Data: 2012
• Identificador Persistente: http://hdl.handle.net/1822/28252
• Origem: RepositóriUM - Universidade do Minho
• Assunto(s): cervical cancer; GGH; Polymorphism; Cisplatin response
• Tipo de Documento: Artigo
• Idioma: Inglês

Descrição

Uncorrected proof Aims: Cervical cancer is the third most frequent cancer in women worldwide, mostly treated with cisplatin-based chemoradiotherapy. Since it is known that folate metabolism might interfere with cisplatin effectiveness, we intended to study the influence of the Gamma Glutamyl Hydrolase -401C > T polymorphism in treatment response in cervical cancer. Methods: We retrospectively reviewed the clinical data of 167 patients with bulky cervical cancer submitted to cisplatin-based chemoradiotherapy. The genotypes of GGH -401C > T SNP were determined by real-time PCR and statistical analysis was performed by chi(2) test and survival analysis. Results: The genotypes of GGH-401C > T were significantly associated with the response to platinum-based chemoradiotherapy. Treatment response was higher in patients carrying the CC genotype, who presented a significant increased chance of treatment response (survival time in months/genotype: 91 for CC Vs 72 for CT/TT; p = 0.035, log rank test). A Cox regression analysis accordingly showed that the presence of the T allele was significantly linked to a worse treatment response (HR = 3.036; CI 95% 1.032-8.934, p = 0.044). Conclusions: The results of our study suggested the potential interest of GGH -401C > T as a predictive factor of the outcome of cervical carcinoma treated with cisplatin-based chemoradiotherapy. (c) 2012 Elsevier B.V. All rights reserved.